SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance

U.S. Markets open in 4 hrs 18 mins

Sanofi (SNY)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
44.09-0.70 (-1.56%)
At close: 4:01PM EDT

46.30 2.22 (5.02%)
Pre-Market: 4:55AM EDT

People also watch
NVSGSKAZNLLYNVO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close44.79
Open44.24
Bid0.00 x
Ask0.00 x
Day's Range43.97 - 44.28
52 Week Range36.81 - 45.95
Volume1,716,079
Avg. Volume1,493,636
Market Cap110.11B
Beta0.75
PE Ratio (TTM)22.81
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.58 (3.46%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire4 hours ago

    Regeneron and Sanofi Receive Positive CHMP Opinion for Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis

    TARRYTOWN, N.Y. and PARIS, April 24, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing authorization of Kevzara® (sarilumab), recommending its approval for use in adult patients with moderately to severely active rheumatoid arthritis. The CHMP recommended the use of Kevzara in combination with methotrexate (MTX) for the treatment of moderately to severely active RA in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs). The European Commission (EC) is expected to make a final decision on the Marketing Authorization Application (MAA) for Kevzara in the European Union in the coming months.

  • Amgen Trumps Regeneron, Sanofi In Cholesterol Drug Sales
    Investor's Business Daily3 days ago

    Amgen Trumps Regeneron, Sanofi In Cholesterol Drug Sales

    Amgen trumped Regeneron and Sanofi this week as prescriptions of its cholesterol-cutting drug grew.

  • Reuters3 days ago

    EMA panel recommends nod for Sanofi, Regeneron's arthritis drug

    A European Medicines Agency panel said on Friday it recommended granting marketing approval to Sanofi and Regeneron's experimental drug to treat rheumatoid arthritis. The Committee for Medicinal Products for Human Use gave a positive opinion on the drug, Kevzara, citing its ability to reduce the signs and symptoms of rheumatoid arthritis. Sarilumab, the active substance of Kevzara, a treatment for adult patients with moderate to severe rheumatoid arthritis, works by blocking a protein called IL-6, which is associated with inflammation.